M&A Moves

Houston-based edtech company makes international acquisition following strategic investments

Raptor Technologies, a Houston-based company providing safety-focused software to schools, has made an acquisition and announced new investment. Graphic via raptortech.com

A Houston company that provides school safety software to schools across the country has made a strategic acquisition.

Raptor Technologies announced last week that it has acquired United Kingdom-based CPOMS, which provides student safeguarding software to schools in the UK. Raptor reported that the M&A activity follows strategic investments from Chicago-based Thoma Bravo and existing investors JMI Equity, a Maryland-based firm, and New York-based Ares Capital. The terms of the deal were not disclosed.

"We are excited to add CPOMS best-in-class wellbeing products to Raptor's market-leading school safety product suite and to welcome the CPOMS team into the Raptor family," says Gray Hall, CEO of Raptor Technologies, in the press release. "Combining CPOMS software and domain expertise with Raptor further advances our mission to protect every child, every school, every day. We are eager to bring the proven capabilities of CPOMS to the US market and continue advancing CPOMS leadership position in the UK."

Raptor was founded to provide schools with a suite of software that can help implement safety across visitor, volunteer, and emergency management services. The software that the CPOMS platform provides targets reporting abuse, cyberbullying, and more.

"Raptor was the perfect fit for CPOMS. Both companies have dedicated themselves to keeping schools and students safe and share very similar cultures," says John Wild, managing director at CPOMS, in the release. "We at CPOMS are excited about joining the Raptor organization and look forward to the enhanced growth opportunities ahead."

Hall will lead the expanded organization, and Wild will transition to managing director of UK Operations for Raptor and CPOMS.

The acquisition was connected to Raptor's recent funding. The company did not disclose the amount raised.

"School safety needs in the US and UK continue to evolve, with solutions for managing the wellbeing and safety of students being paramount," says Adam Solomon, a principal at Thoma Bravo, in the release. "Through this investment and acquisition, we see tremendous potential for Raptor to extend its market leadership in K-12 school safety and its continued deployment of innovative solutions to schools in the US and UK."

The Houston company was founded in 2003. In 2018, Raptor received investment from JMI Equity.

"Combining CPOMS with Raptor creates a company with unique capabilities to help schools manage the safety and wellbeing of their students," says Bob Nye, general partner at JMI Equity, in the release. "We're excited about this acquisition and the strategic opportunity ahead."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted